{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:13:47Z","timestamp":1777936427537,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Vasc Med"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) of the BCR-ABL fusion protein have dramatically changed the mortality of chronic myeloid leukemia (CML) but they carry a risk of serious vascular morbidity. While TKIs do not cure CML, daily oral administration of a TKI can control CML and TKIs are chronic medications. Interestingly, vascular complications can occur at any time a patient is on a TKI. Therefore, it is imperative that all care team members and patients are aware of and watching for possible vascular complications. In the following review, a case of arterial thrombosis secondary to the TKI ponatinib is presented as well as a discussion of thrombotic and vascular adverse events reported with TKIs. TKIs are metabolized through the cytochrome P450 system and important drug interactions to consider are reviewed. Finally, we present a multidisciplinary approach to the management of patients with CML on TKIs.<\/jats:p>","DOI":"10.1177\/1358863x20906868","type":"journal-article","created":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T02:30:41Z","timestamp":1587177041000},"page":"246-254","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors"],"prefix":"10.1177","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3507-2296","authenticated-orcid":false,"given":"Lavanya","family":"Kondapalli","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of Colorado, Aurora, CO, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Worth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riem","family":"Hawi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garima","family":"Arora","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie G","family":"Lenneman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, University of Alabama at Birmingham, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"key":"bibr1-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104753"},{"key":"bibr2-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0624-2"},{"key":"bibr3-1358863X20906868","unstructured":"National Institutes of Health. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Leukemia \u2013 chronic myeloid leukemia (CML), https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html (2019, accessed 22 July 2019)."},{"key":"bibr4-1358863X20906868","unstructured":"Novartis Pharmaceuticals Corp. GLEEVEC (imatinib mesylate) [package insert]. East Hanover, NJ: Novartis, 2001."},{"key":"bibr5-1358863X20906868","unstructured":"Bristol-Myers Squibb Company. SPRYCEL (dasatinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb, 2006."},{"key":"bibr6-1358863X20906868","unstructured":"Pfizer, Inc. BOSULIF (bosutinib) [package insert]. New York, NY: Pfizer, 2012."},{"key":"bibr7-1358863X20906868","unstructured":"Novartis Pharmaceuticals Corp. TASIGNA (nilotinib) [package insert]. East Hanover, NJ: Novartis, 2007."},{"key":"bibr8-1358863X20906868","unstructured":"ARIAD Pharmaceuticals, Inc. ICLUSIG (ponatinib) [package insert]. Cambridge, MA: ARIAD, 2012."},{"key":"bibr9-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0071"},{"key":"bibr10-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"bibr11-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"bibr12-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.36"},{"key":"bibr13-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"bibr14-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-319038"},{"key":"bibr15-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0779"},{"key":"bibr16-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"bibr17-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.63"},{"key":"bibr18-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"bibr19-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4718"},{"key":"bibr20-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.110"},{"key":"bibr21-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.01.004"},{"key":"bibr22-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"bibr23-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.134"},{"key":"bibr24-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"bibr25-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.129221"},{"key":"bibr26-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"bibr27-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2606"},{"key":"bibr28-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24536"},{"key":"bibr29-1358863X20906868","unstructured":"US Food & Drug Administration. FDA Drug Safety Communication: Sprycel (dasatinib) and risk of pulmonary arterial hypertension, https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-sprycel-dasatinib-and-risk-pulmonary-arterial-hypertension (2017, accessed 29 December 2019)."},{"key":"bibr30-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"bibr31-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86249"},{"key":"bibr32-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"bibr33-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24174"},{"key":"bibr34-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.05.008"},{"key":"bibr35-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2015.09.003"},{"key":"bibr36-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.086355"},{"key":"bibr37-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117464"},{"key":"bibr38-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4766.4766"},{"key":"bibr39-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294330"},{"key":"bibr40-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3413-7"},{"key":"bibr41-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70579-5"},{"key":"bibr42-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.08.004"},{"key":"bibr43-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2820-x"},{"key":"bibr44-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.10.002"},{"key":"bibr45-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.012521"},{"key":"bibr46-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22137"},{"key":"bibr47-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.008820"},{"key":"bibr48-1358863X20906868","unstructured":"US Department of Health and Human Services. Physical Activity Guidelines for Americans, 2nd edition, https:\/\/health.gov\/sites\/default\/files\/2019-09\/Physical_Activity_Guidelines_2nd_edition.pdf (2018, accessed 5 March 2020)."},{"key":"bibr49-1358863X20906868","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.006"}],"container-title":["Vascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1358863X20906868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1358863X20906868","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1358863X20906868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:30:48Z","timestamp":1777692648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1358863X20906868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1177\/1358863X20906868"],"URL":"https:\/\/doi.org\/10.1177\/1358863x20906868","relation":{},"ISSN":["1358-863X","1477-0377"],"issn-type":[{"value":"1358-863X","type":"print"},{"value":"1477-0377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]}}}